Disease · MONDO_0007661

Tourette syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Tourette syndrome. Diseases, record MONDO_0007661. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007661

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Tourette syndrome; Open Targets
Open Targets ID: MONDO_0007661; Open Targets
Other names: Tourette disease, Tourette's syndrome, motor-verbal tic disorder; Open Targets
Disease Ontology: DOID:11119; Disease Ontology
MeSH: D005879; MeSH
NCI Thesaurus: C35078; NCI Thesaurus
Orphanet: ORPHA:856; Orphanet
Highest stage of its drugs: Approval, for 3 of its 36 drugs, from DailyMed; Open Targets

Drugs36

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	DailyMed	9	8	8	Drugs and targets
HALOPERIDOL	CHEMBL54	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
PIMOZIDE	CHEMBL1423	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
DEUTETRABENAZINE	CHEMBL3137326	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
NABIXIMOLS	CHEMBL3833333	Small molecule	Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GUANFACINE	CHEMBL862	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PRAMIPEXOLE	CHEMBL301265	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TIAPRIDE	CHEMBL84158	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VALBENAZINE	CHEMBL2364639	Small molecule	Phase 2	ClinicalTrials.gov and TTD	9	8	8	Drugs and targets

1 to 10 of 36

See all 36 drugs

Targets65

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	7	D2-like dopamine receptor agonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptor agonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D(3) dopamine receptor	5	D2-like dopamine receptor agonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor antagonist; Dopamine receptor agonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	5	Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD4	D2-like dopamine receptor	4	D2-like dopamine receptor agonist; D2-like dopamine receptor inverse agonist; Dopamine receptor agonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
SLC18A2	Synaptic vesicular amine transporter	4	Synaptic vesicular amine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6571	Drugs and targets
DRD1	D(1A) dopamine receptor	3	Dopamine D1 receptor antagonist; Dopamine receptor agonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1812	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
DRD5	Dopamine receptor	2	Dopamine receptor agonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1816	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets

1 to 10 of 65

See all 65 targets

Trials49

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03567291	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents	Phase 3	228	2021-03-23	Tourette Syndrome	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT01416441	Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder	Phase 3	170	2021-10-07	Tourette's Disorder	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03571256	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)	Phase 3	158	2020-06-09	Tourette Syndrome	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02879578	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome	Phase 2	155	2021-04-29	Tourette Syndrome	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT04007991	Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents	Phase 2	153	2023-10-04	Tourette Syndrome	ECOPIPAM	Its record names the disease	ClinicalTrials.gov
NCT01418339	Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder	Phase 3	135	2021-10-07	Tourette's Disorder	ARIPIPRAZOLE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01727700	Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder	Phase 3	133	2015-02-13	Tourette's Disorder, Tic Disorder	ARIPIPRAZOLE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03325010	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Phase 2	127	2021-06-28	Tourette Syndrome	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02581865	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome	Phase 2	124	2020-05-07	Tourette Syndrome	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT04114539	Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension	Phase 2	124	2023-12-01	Tourette Syndrome in Children, Tourette Syndrome in Adolescence	ECOPIPAM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 49

See all 49 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ecopipam HCI 2 mg/kg/Day vs Placebo: deaths from any cause	0 of 76	0 of 77	153	NCT04007991	Trial comparisons
Ecopipam HCI 2 mg/kg/Day vs Placebo: serious adverse events	2 of 76	1 of 77	153	NCT04007991	Trial comparisons
Aripiprazole vs Placebo: deaths from any cause	0 of 90	0 of 45	135	NCT01418339	Trial comparisons
Aripiprazole vs Placebo: serious adverse events	3 of 90	0 of 45	135	NCT01418339	Trial comparisons
Valbenazine vs Placebo: deaths from any cause	0 of 59	0 of 62	121	NCT03325010	Trial comparisons
Valbenazine vs Placebo: serious adverse events	0 of 59	1 of 62	121	NCT03325010	Trial comparisons
TEV-50717 vs Placebo: deaths from any cause	0 of 58	0 of 59	117	NCT03452943	Trial comparisons
TEV-50717 vs Placebo: serious adverse events	0 of 58	0 of 59	117	NCT03452943	Trial comparisons
Valbenazine vs Placebo: Participants Who Are a Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) Responder at Week 12	18 of 43	21 of 54	97	NCT03325010	Trial comparisons
Valbenazine vs Placebo: Participants Who Are a Clinical Global Impression of Tourette Syndrome Improvement (CGI-TS-Improvement) Responder at Week 12	24 of 43	12 of 54	97	NCT03325010	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27027204	RESULT	1	PubMed
40082070	DERIVED	1	PubMed
39026306	DERIVED	1	PubMed
34708399	DERIVED	1	PubMed
34661664	DERIVED	1	PubMed
34609495	DERIVED	1	PubMed
34117788	DERIVED	1	PubMed
33324255	DERIVED	1	PubMed
30192018	DERIVED	1	PubMed
28686474	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007661

GET https://conductscience.org/api/diseases/v1/MONDO_0007661/drugs?page=2

API reference For AI assistants